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Aim: The aim of the study was to verify the dose distribution optimisation method in pulsed
brachytherapy.
Background: The pulsed-dose rate brachytherapy is a very important method of breast tumour
treatment using a standard brachytheraphy equipment. The appropriate dose distribution
round an implant is an important issue in treatment planning. Advanced computer systems
of  treatment planning are equipped with algorithms optimising dose distribution.
Materials and methods: The wax-parafﬁn phantom was constructed and seven applicators
were  placed within it. Two treatment plans (non-optimised, optimised) were prepared. The
reference points were located at a distance of 5 mm from the applicators’ axis. Thermolu-
minescent detectors were placed in the phantom at suitable 35 chosen reference points.
Results: The dosimetry veriﬁcation was carried out in 35 reference points for the plans before
and after optimisation. Percentage difference for the plan without optimisation ranged
from −8.5% to 1.4% and after optimisation from −8.3% to 0.01%. In 16 reference points,
the  calculated percentage difference was negative (from −8.5% to 1.3% for the plan without
optimisation and from −8.3% to 0.8% for the optimised plan). In the remaining 19 points
percentage difference was from 9.1% to 1.4% for the plan without optimisation and from
7.5% to 0.01% for the optimised plan.
No statistically signiﬁcant differences were found between calculated doses and doses
measured at reference points in both dose distribution non-optimised treatment plans and
optimised treatment plans.Conclusions: No statistically signiﬁcant differences were found in dose values at reference
points between doses calculated by the treatment planning system and those measured by
TLDs. This proves the consistency between the measurements and the calculations.
©  2013 Published by Elsevier Urban & Partner Sp. z o.o. on behalf of Greater Poland Cancer∗ Corresponding author. Tel.: +48 618850521; fax: +48 618850723.
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1.  Background
A pulsed-dose rate brachytherapy (PDR) is one of the most
commonly used methods of breast cancer treatment, which
has been known and applied since the early 1990s. The
method employs the isotope 129Ir with initial activity of
15–37 GBq (0.5–1.0 Ci) and dose rate of 0.5–1.0 Gy/h. An essen-
tial part of this method is the obtaining of a proper
dose distribution around an implant (or implants). Those
distributions can be derived from dose distribution optimi-
sation algorithms used by IT treatment planning systems.
They require, however, a precise dosimetric veriﬁcation in
order to ensure a high quality of treatment and patient
safety.9–13,15,23–26
2.  Aim
The aim of the study was to compare measured doses with
thermoluminescent detectors and calculated by the Plato
treatment planning system for treatment plans before and
after the optimisation.
3.  Material
3.1.  Tissue-like  phantom
A permanent phantom was made to establish dose distribu-
tions; it was constructed from a mixture of wax and parafﬁn.
The material used had a mean atomic number of Zm = 6.82,
and a mean density of m = 0.9 g/cm3. It constituted a good
approximation of soft tissues, as the properties of the mix-
ture used to build it roughly corresponded to those of water
(Zm = 6.62, m = 1.0 g/cm3). The phantom consisted of two parts
and both of them were blocks made from a mixture of wax
and parafﬁn, sized 16 cm × 14 cm × 1 cm (Fig. 1). Four applica-
tors for radiation source were placed centrally in the lower
part at 1 cm intervals, and three in the upper part at 1 cm
intervals.15 Thermoluminescent detectors (TLD) were placed
on both parts of the phantom to measure doses. The TLDs
were placed over the applicators at 2 cm intervals – ﬁve TLD
per applicator.
3.2.  Thermoluminescent  detectors
Dose measurements at reference points set with the Plato
treatment planning system were made using Harshaw TLD-
100 thermoluminescent detectors in the form of lithium
ﬂuoride (LiF) sinters sized 3.0 mm × 3.0 mm × 0.9 mm.  Dose
values were read out by Harshaw 3500 TLD Reader. The
detectors were calibrated in a cobalt 60 beam (Theratron 780
radiotherapy unit) with a mean radiation energy of 1.25 MV,
radiation ﬁeld of 20 cm × 20 cm and prescribed dose of 200 cGy.
The calibration process was repeated ﬁve times. Each of the
detectors was assigned a calibration ratio. The detectors were
annealed after each read-out.4,11,17,19iotherapy 1 8 ( 2 0 1 3 ) 139–147
3.3.  Dosimetry  ﬁlms
To make a quality veriﬁcation of dose distributions calculated
with the Plato treatment planning system, Gafchromic EBT
dosimetry ﬁlms were used after having been cut down  to the
size of 75 mm × 75 mm.  The insertion of the ﬁlms into the
tissue-like phantom did not distort the density of the medium,
as mean density of the ﬁlm was similar to that of tissues
(water). A dose-dependent darkening was visible right after a
radiation session as blue tints and shades. The ﬁlm response,
i.e. the dependence of optical density on radiation dose, was
linear for a wide range of doses (from approx. 0.1 Gy to 10 Gy).
The darkening of a ﬁlm in this case will depend only on the
total dose absorbed during a measurement.1–3,5,6,14,16,18–20
4.  Method
4.1.  Dose  distribution  calculations
In the case of pulsed-dose rate brachytherapy, a treatment
plan contains information on dose distributions and their
corresponding active source dwell positions along the appli-
cator and source dwell times in particular positions. The dose
distribution thus established depends on the above men-
tioned parameters and on physical properties of the irradiated
medium. The treatment plan in this study was developed
using Nucletron Plato v. 14.1.3. planning system. Thirty-ﬁve
reference points were set. The placement of detectors was
veriﬁed by an integrated brachytherapy unit (IBU). Received
X-ray images were used to set a radiation volume and develop
a treatment plan. Each source dwell position was assigned a
reference point located 5 mm from each of the applicator axis.
Of 119 reference points, 35 were selected (A1–A35) and set at
2 cm intervals along each applicator axis. Thirty-ﬁve thermo-
luminescent detectors were selected based on variation ratio
and put at these points (A1–A35). The doses derived with the
Plato system were then subjected to dosimetric veriﬁcation.
Then, dose distributions of particular treatment plans (Fig. 2)
were optimised and doses veriﬁed at reference points. A point
optimisation was made, with source dwell positions diversi-
ﬁed so that doses received at reference points was equal to a
prescribed value.
4.2.  Dose  distribution  measurements
The dosimetric veriﬁcation of dose distributions for particular
plans consisted of two stages. In stage one, doses were mea-
sured at reference points for non-optimised treatment plans,
while in stage two, they were measured for the optimised
ones. The prescribed dose was 3 Gy (6 pulses, 0.5 Gy each). The
location of thermoluminescent detectors was identical as the
location of the pre-set reference points. In the studied case,
the distance covered by the radioactive isotope from the end of
the applicator unit to the farthest dwell position was 1159 mm
(maximum distance is 1400 mm).  The veriﬁcation of dose dis-
tributions for particular treatment plans was also made with
EBT dosimetry ﬁlms. The ﬁlms were inserted in the phantom
after being properly clipped. The darkening distributions of
the dosimetry ﬁlms were recorded in a 16-bit grey scale and
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Fig. 1 – The wax and parafﬁn phantom for dosimetric veriﬁcation of dose distributions in pulsed-dose rate brachytherapy:
(a) a scheme of the phantom, (b) image of the phantom with applicators and thermoluminescent detectors, (c) the lower part
of the phantom and (d) the upper part of the phantom.
Fig. 2 – A presentation showing isodose distributions for a
non-optimised plan developed by the Plato treatment
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number of TLDs and their ratio mean the detectors used tolanning system.
hen transformed into isodose images by means of Mephisto
oftware.7,8
.3.  Comparison  between  calculated  and  measured
oses
he Wilcoxon and sign tests were used to compare doses
alculated at reference points by the treatment planningsystem with those measured by thermoluminescent detec-
tors. These tests are made for two dependent variables. They
serve to check the signiﬁcance of differences between two
dependent samples. As its name suggests, the sign test is
based on signs of differences between successive pairs of
results and, therefore, is used primarily for qualitative com-
parisons.
5.  Results
5.1.  Calibration  of  thermoluminescent  detectors
The calibration process was carried out for 50 thermolumi-
nescent detectors. Prescribed dose was 2 Gy. Five series of
calibration measurements were made. A measure of disper-
sion (standard deviation and variation ratio) and a measure of
central tendency (arithmetic mean) were calculated for each
detector.27 Additionally, each detector was assigned a calibra-
tion ratio which allowed to determine absorbed radiation dose.
They were deﬁned as follows:where: Dk, value of dose pre-
scribed for the TLD calibration process, x˜ mean value derived
from detector read-outs.
The results of calibration of thermoluminescent detectors
and value of calibration ratio are shown in Table 1. The markedmeasurements.
The arithmetic mean with standard deviation is presented
in Fig. 3.
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Table 1 – TLD calibration measurements and the results of the calibration factor. Marked No., number of detector; x¯, the
average arithmetic; SD, standard deviation; , coefﬁcient of variation; Wk, calibration factor.
No Next measurements [C] x¯ [C] SD [C]  [%] Wk [Gy/C]
1 2 3 4 5
1 5.23 5.15 4.91 4.88 4.99 5.03 0.15 3.04 0.40
2 4.40 2.86 4.27 4.30 4.34 4.03 0.66 16.28 0.46
3 4.11 2.28 4.06 4.13 4.12 3.74 0.82 21.82 0.49
4 4.83 3.07 4.56 4.69 4.42 4.31 0.71 16.49 0.45
5 4.38 4.21 4.16 4.37 4.26 4.27 0.10 2.26 0.47
6 4.56 4.46 4.25 4.47 4.56 4.46 0.13 2.85 0.44
7 4.21 3.99 4.08 4.21 4.26 4.15 0.11 2.66 0.47
8 4.31 4.12 4.06 4.06 2.56 3.82 0.71 18.66 0.78
9 4.82 4.68 4.73 4.54 4.68 4.69 0.10 2.17 0.43
10 5.02 4.85 4.79 3.80 3.87 4.47 0.58 13.03 0.52
11 4.73 4.65 4.65 4.58 4.67 4.66 0.05 1.12 0.43
12 5.23 5.23 4.94 5.01 5.03 5.09 0.13 2.64 0.40
13 5.17 4.93 5.04 4.80 4.92 4.97 0.14 2.87 0.41
14 5.10 5.16 5.03 5.07 5.08 5.09 0.05 0.91 0.39
15 4.90 4.82 4.63 4.52 4.58 4.69 0.16 3.48 0.44
16 4.59 4.72 4.61 4.48 4.60 4.60 0.08 1.81 0.43
17 4.76 4.79 4.73 4.48 4.72 4.70 0.12 2.65 0.42
18 5.20 5.20 4.84 4.69 4.62 4.91 0.28 5.63 0.43
19 4.49 4.59 4.52 4.32 4.31 4.45 0.13 2.82 0.46
20 4.39 4.30 4.20 4.07 4.13 4.22 0.13 3.03 0.48
21 4.91 4.99 4.78 4.78 4.85 4.86 0.09 1.86 0.41
22 4.54 4.75 4.52 4.58 4.59 4.59 0.09 1.97 0.44
23 4.70 4.50 4.44 4.45 4.59 4.54 0.11 2.42 0.44
24 4.93 5.20 5.06 5.06 5.02 5.06 0.10 1.93 0.40
25 4.97 4.86 4.81 4.92 4.90 4.89 0.06 1.20 0.41
26 4.55 4.71 4.33 4.44 4.52 4.51 0.14 3.09 0.44
27 4.86 4.83 4.71 4.64 4.73 4.75 0.09 1.90 0.42
28 4.74 4.67 4.39 4.60 4.51 4.58 0.13 2.94 0.44
29 4.93 4.96 4.91 4.74 4.90 4.89 0.09 1.79 0.41
30 4.28 4.26 4.24 4.29 4.31 4.27 0.03 0.67 0.46
31 4.86 4.77 4.81 4.80 4.69 4.79 0.06 1.33 0.43
32 4.70 4.78 4.61 4.65 4.56 4.66 0.08 1.82 0.44
33 4.88 4.99 4.86 4.86 4.87 4.89 0.05 1.12 0.41
34 4.81 4.80 4.62 4.57 4.53 4.67 0.13 2.83 0.44
35 4.67 4.80 4.55 4.60 4.48 4.62 0.12 2.68 0.45
36 5.05 5.10 4.95 4.68 4.93 4.94 0.16 3.31 0.41
37 4.71 4.75 4.75 4.85 4.78 4.77 0.05 1.06 0.42
38 4.81 4.86 4.60 4.71 4.72 4.74 0.10 2.14 0.42
39 4.85 5.02 4.93 4.89 4.91 4.92 0.06 1.26 0.41
40 3.94 4.77 4.71 4.54 4.54 4.50 0.33 7.30 0.44
41 4.50 4.63 4.52 4.50 4.43 4.52 0.07 1.60 0.45
42 4.71 4.85 4.52 4.69 4.73 4.70 0.12 2.47 0.42
43 4.79 4.69 4.53 4.79 4.80 4.72 0.11 2.38 0.42
44 4.97 4.77 4.72 4.74 4.81 4.80 0.10 2.11 0.42
45 4.63 4.74 4.36 4.50 4.67 4.58 0.15 3.33 0.43
46 4.93 4.75 4.71 4.72 4.77 4.77 0.09 1.87 0.42
47 4.56 4.83 4.76 4.63 4.56 4.67 0.12 2.64 0.44
48 4.37 4.51 4.47 4.44 4.47 4.45 0.05 1.12 0.45
49 4.77 4.51 4.61 4.61 4.62 4.62 0.09 2.03 0.43
.52 50 4.50 4.70 4.63 4.40 4
5.2.  Dose  measurements  at  reference  points
Out of 50 thermoluminescent detectors, 35 with the lowest
variation ratios were selected for preliminary dose measure-
ment. The measurements were made at 35 reference points
(A1–A35) in a wax and parafﬁn phantom using thermolumi-
nescent detectors. Three series of dose measurements were
performed. A measure of dispersion and measure of central
tendency were established for each reference point. Fig. 44.55 0.11 2.50 0.44
provides a graphic representation of arithmetic average with
standard deviation based on the results of dose measurements
at 35 reference points (A1–A35) for non-optimised and opti-
mised treatment plants.
Using the measurement results and calculated statistical
measures, dose reference points were set. Table A1 shows
the dose designated on the basis of TLD measurements for
both treatment plans with and without optimisation. Com-
parison of mean values of measured doses on the basis
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Fig. 3 – Averaged results of thermoluminescent detector
calibration with a standard deviation.
o
t
m
s
F
2
m
f
t
Fig. 6 – Images generated after the irradiation of the EBT
dosimetry ﬁlm: (a) before and (b) after optimisation.
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Dose distribution veriﬁcation was also made with Gafchromic
EBT dosimetry ﬁlms. The ﬁlms were placed in the phantom
parallel to the catheter axis. Fig. 5 shows images obtained
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Fig. 7 – Dose distribution received with (a) a non-optimised Plato system, (b) an optimised Plato system, (c) a non-optimised
EBT ﬁlm and (d) an optimised EBT ﬁlm.
distribution based on the analysis of RBT dosimetry ﬁlm per-
formed with Mephisto software18 (Fig. 7).
5.4.  Comparison  between  calculated  and  measured
doses
Doses calculated by the Plato planning system were compared
statistically with those measured by thermoluminescent
detectors for both non-optimised and optimised treatment
plans. The dosimetry veriﬁcation was performed in 35 refer-
ence points for the plans before and after optimisation. For
each point, the arithmetic mean, standard deviation (SD) and
coefﬁcient of variation were calculated. For the plan without
optimisation, in 7 points, the coefﬁcient of variation reached
between 5% and 10%, providing a normal variation, while in 28
points, below 4% which indicates a very low volatility. For the
optimisation plan, 19 points ranged from 5% to 10% and at 16
points the coefﬁcient of variation reached a value lower than
4% providing a very low volatility, which indicates the preci-
sion used in the detectors. Using the results of measurements,
the dose in reference points was determined. The values were
averaged and the percentage difference between calculated
Table 2 – Comparative statistical analysis of the plans before an
Descriptive statistics Plan without optimisa
Plato [Gy] T
N 35 3
Average 2.81 
Minimum 1.90 
Maximum 3.75 
SD 0.59 
Table 3 – Results of statistical analysis before and after optimis
sign test (Sign test).
A pair of variables tested Plan without optimi
Level p 
Test sign 
Plato vs. TLD for 35 N 0.74 doses in the treatment planning system and the dose obtained
from dosimetric measurements was established. Percentage
difference for the plan without optimisation ranged from
−8.5% to 1.4% and for the plan with optimisation from −8.3%
to 0.01%. For 16 reference points, the percentage difference
was negative (for the plan without optimisation from −8.5% to
−1.3%, and for the plan with optimisation from −8.3% to 0.8%),
which means that the measured dose at these points was
smaller than the calculated dose. In the remaining 19 points,
percentage difference was positive (for the plan without opti-
misation from 9.1% to 1.4% and for plan with optimisation
from 7.5% to 0.01%) which proving that dose measured at
these points was greater than the calculated dose. No sta-
tistically signiﬁcant differences were found in dose values at
reference points between doses calculated by the treatment
planning system and those measured by TLDs. This proves
the consistency between the measurements and the calcu-
lations. The results of descriptive statistics are presented in
Table 2. The results of statistical veriﬁcation of compliance
of calculated doses by Plato treatment planning system and
measured at the points of reference by average of TLD before
and after optimisation are presented in Table 3. The analysis
d after optimisation.
tion Plan with optimisation
LD [Gy] Plato [Gy] TLD [Gy]
5 35 35
2.77 2.99 2.99
1.94 2.87 2.73
3.55 3.08 3.29
0.48 0.06 0.15
ation. The values of the parameter p Wilcoxon test and
sation Plan with optimisation
Level p
Wilcoxon Test sign Wilcoxon
0.14 0.74 0.69
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sed the Sign test and Wilcoxon tests. The results were ana-
ysed at the signiﬁcance level of  ˛ = 0.05 by means of Statistica
.0 software.19,21,22
.  Discussion
.1.  Calibration  of  thermoluminescent  detectors
he variation ratio for the 50 thermoluminescent detectors
ubjected to calibration was very low, indicating small differ-
nces in successive measurements, or in other words, high
recision of the applied thermoluminescent detectors. Only
n four cases were variation ratios higher than 10%, meaning
 large variation.
.2.  Dose  measurements  at  reference  points
osimetric veriﬁcation was performed at 35 reference points
A1–A35) for treatment plans before and after optimisation.
rithmetic mean, standard deviation (SD) and variation ratio
ere all calculated for each point. For the non-optimised
lans, the variation ratio at seven points came within the
ange of 5–10%, suggesting a normal variation, and in 28 points
t was below 4% signifying a low variation. For the optimised
lans, 19 points came within the rage of 5–10%, and for 16
oints the variation ratio was found to be below 4% mean-
ng a low differentiation of results and high accuracy of the
pplied detectors. Based on the measurement results, dose
izes at reference points were established. The values thus
btained were averaged and then a percent difference was set
etween doses calculated in the treatment planning system
nd those derived from dosimetric measurements. The per-
ent difference for the non-optimised plan was in the range of
8.5% to 1.4%, whereas for the optimised plan it ranged from
8.3% to 0.01%. At 16 reference points, the percent difference
as negative (for non-optimised plan: from −8.5% to −1.3%;
or optimised plan: from −8.3% to −0.8%), meaning that doses
easured at those points were lower than those calculated
y the treatment plan. At the remaining 16 reference points,
he percent difference was positive (for non-optimised plan:
rom 9.1% to 1.4%; for optimised plan: from 7.5% to 0.01%),
eaning that doses measured at those points were higher
han those calculated by the treatment plan. The reason for
he existing disparity between the calculated and measured
oses may lie in the occurrence of substantial dose gradients
n the radiated volume. It may also be caused by differences
n the mean density and mean atomic number between the
oft tissue (water) and the material the phantom was made
f, the phantom being, after all, just an approximation of the
onditions inside a patient’s body. The existing disparity my
lso be accounted for by displacements of thermoluminescent
etectors in the process of their being placed in the phantom.
he phantom also made it possible to verify dose distributions
alculated by the Plato treatment plan before and after opti-
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EBT dosimetry ﬁlms. Qualitative features of isodose distribu-
tions for calculated doses were compared with those received
from the digitalisation of dosimetry ﬁlms. Images thus gen-
erated enabled a visual comparison of isodose shapes and
locations as well as a radiation ﬁeld marked by those iso-
doses. The comparison revealed no signiﬁcant differences
between dose distribution calculated by the Plato treatment
planning system and that measured by dosimetry ﬁlms. The
result demonstrates that calculation algorithms of the Plato
treatment planning system provide reliable dose distributions
in planned radiation volumes typical for pulsed-dose rate
brachytherapy.
6.3.  Comparison  between  calculated  and  measured
doses
The study employed nonparametric tests for dependent vari-
ables: the Wilcoxon test and sign test. Received p values
were analysed at the statistical signiﬁcance level of  ˛ = 0.05.
In the case of very small samples (3 measurements), all the
results had p > 5%. The received results of p > 0.05 do not
provide grounds for declining the zero hypothesis, that is the
assumption that there are no signiﬁcant differences in val-
ues at reference points between doses calculated by the Plato
treatment planning system and those measured with thermo-
luminescent detectors. The received statistics allow the claim
that calculation algorithms of the Plato treatment planning
system provide reliable dose distributions in planned target
volumes for pulsed-dose rate brachytherapy.
7.  Conclusion
The study also conﬁrmed the dosimetric correctness of the
algorithm used for calculation of doses in the Plato system
in pulsed-dose rate brachytherapy. No statistically signiﬁcant
differences were found between calculated and measured
doses and the correctness of the dose distribution opti-
misation algorithm was veriﬁed. No statistically signiﬁcant
differences were found in dose values at reference points
between doses calculated by the treatment planning system
and those measured by TLDs. This proves the consistency
between the measurements and the calculations.
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Table A1 – Measured doses in 35 of reference points for treatment plans without optimisation and with optimisation.
Reference points Measured doses [Gy]
Without optimisation With optimisation
Dz1 Dz2 Dz3 Dz1 Dz2 Dz3
A1 2.12 2.44 2.34 3.08 3.20 2.80
A2 2.69 2.57 2.63 3.13 2.81 3.09
A3 2.34 2.37 2.41 3.04 3.21 3.13
A4 2.94 2.94 2.98 2.80 2.70 2.81
A5 3.42 3.34 3.26 2.69 2.80 2.71
A6 3.01 2.96 3.08 3.08 2.75 3.08
A7 3.52 3.53 3.53 2.74 2.80 2.79
A8 3.39 3.49 3.48 3.25 3.14 3.22
A9 3.02 3.16 3.03 2.76 3.18 2.72
A10 3.05 3.07 3.07 3.23 2.74 3.04
A11 3.26 3.23 3.29 2.66 3.23 2.80
A12 2.99 3.03 3.01 3.05 2.69 2.71
A13 2.41 2.35 2.32 2.74 3.00 2.77
A14 2.27 2.28 2.54 3.08 2.73 3.01
A15 2.32 2.31 2.40 2.70 3.05 2.98
A16 2.09 2.05 2.05 3.31 2.85 2.78
A17 2.45 2.45 2.05 2.81 2.73 3.13
A18 2.34 2.34 2.34 3.31 2.75 3.29
A19 2.00 2.01 2.05 2.87 2.88 2.75
A20 2.65 2.57 2.59 2.90 3.34 3.24
A21 3.15 3.13 3.15 3.21 2.85 2.89
A22 3.52 3.53 3.61 2.86 3.21 3.26
A23 2.94 2.65 2.64 2.91 2.77 2.81
A24 2.73 2.73 2.64 3.27 3.21 3.18
A25 3.32 3.28 3.23 3.20 3.28 3.27
A26 3.26 3.17 3.22 3.25 2.89 2.92
A27 2.76 3.09 2.79 2.87 2.79 2.80
A28 2.62 2.93 2.65  3.22 3.33 3.31
A29 3.48 3.57 3.61 3.23 3.21 3.22
A30 3.18 3.01 3.16 2.77 3.19 3.19
A31 2.66 2.65 2.68 2.85 2.76 2.89
A32 2.01 2.05 2.05 2.94 2.87 2.93
A33 2.39 2.40 2.47 2.76 3.23 2.96
A34 2.41 2.40 2.44 2.88 3.25 2.81
A35 2.02 1.78 2.02 3.22 2.88 3.22
Table A2 – The average measured dose and calculated dose metrics in 35 reference points for treatment plan
optimisation and without optimisation. Marked Dz, average measured dose; Do, calculated dose; SD, standard deviation;
R, percentage difference.
Reference points Without optimisation With optimisation
Dz [Gy] Do [Gy] SD [Gy] R [%] Dz [Gy] Do [Gy] SD [Gy] R [%]
A1 2.30 2.23 0.16 −3.31 3.03 2.92 0.21 −3.73
A2 2.63 2.46 0.06 −7.06 3.01 2.93 0.17 −2.57
A3 2.37 2.21 0.04 −7.33 3.12 2.92 0.08 −7.17
A4 2.95 3.24 0.02 8.83 2.77 2.95 0.06 6.08
A5 3.34 3.60 0.08 7.22 2.73 2.96 0.06 7.80
A6 3.02 3.21 0.06 6.10 2.97 2.95 0.19 −0.79
A7 3.53 3.38 0.01 −4.35 2.78 2.95 0.03 5.66
A8 3.45 3.75 0.06 7.99 3.20 2.96 0.06 −8.29
A9 3.07 3.35 0.08 8.48 2.89 2.94 0.25 1.83
A10 3.06 3.22 0.01 4.91 3.00 2.94 0.24 −2.31
A11 3.26 3.59 0.03 9.11 2.90 2.95 0.30 1.81
A12 3.01 3.20 0.02 5.89 2.82 2.93 0.20 4.02
A13 2.36 2.20 0.05 −7.23 2.84 2.87 0.14 1.13
A14 2.36 2.43 0.15 2.59 2.94 2.89 0.19 −1.66
A15 2.35 2.18 0.05 −7.40 2.91 2.87 0.19 −1.54
A16 2.06 1.90 0.02 −8.54 2.98 3.04 0.29 1.88
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Table A2 – (Continued)
Reference points Without optimisation With optimisation
Dz [Gy] Do [Gy] SD [Gy] R [%] Dz [Gy] Do [Gy] SD [Gy] R [%]
A17 2.32 2.24 0.23 −3.48 2.89 3.02 0.21 4.24
A18 2.34 2.25 0.00 −4.30 3.12 3.02 0.32 −3.17
A19 2.02 1.90 0.03 −6.20 2.83  3.01 0.07 5.86
A20 2.60 2.78 0.04 6.48 3.16 3.07 0.23 −3.04
A21 3.14 3.32 0.01 5.45 2.99 3.04 0.20 1.70
A22 3.55 3.33 0.05 −6.62 3.11 3.04 0.22 −2.24
A23 2.74 2.78 0.17 1.37 2.83 3.04 0.07 6.94
A24 2.70 2.93 0.05 7.75 3.22 3.07 0.04 −4.93
A25 3.28 3.49 0.05 6.09 3.25 3.04 0.04 −6.96
A26 3.21 3.50 0.04 8.08 3.02 3.04 0.20 0.72
A27 2.88 2.92 0.18 1.40 2.82 3.05 0.05 7.45
A28 2.73 2.80 0.17 2.28 3.29 3.08 0.06 −6.66
A29 3.55 3.34 0.06 −6.37 3.22 3.05 0.01 −5.59
A30 3.12 3.35 0.09 6.84 3.05 3.05 0.24 0.01
A31 2.67 2.79 0.01 4.58 2.83 3.06 0.07 7.39
A32 2.04 1.91 0.02 −6.37 2.91 3.08 0.04 5.25
A33 2.42 2.25 0.04 −7.38 2.98 3.05 0.24 2.23
A34 2.42 2.26 0.02 −7.04 2.98 3.05 0.23 2.33
r
1
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